Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces the opening of its new state-of-the-art
manufacturing and services facility in Louisville, KY, in the US.
The large, 65,800 ft2 (6,113 m2) facility functions as the Group’s
central genomics laboratory in North America, focusing on the
custom production of DNA and RNA oligonucleotides synthetic gene
synthesis, and genomics services including DNA sequencing,
synthetic biology, and next generation sequencing (NGS).
As a leader in analytical laboratory technology, Eurofins
continues to expand its global infrastructure of advanced
laboratories. Since 2005, Eurofins has invested over $800,000,000
dollars to add or modernize over 350,000m2 of laboratory surface to
its network, and plans to add another 120,000m2 by the end of 2017.
The Louisville, KY facility will be one of the newest and most
advanced genomics facilities in the world. As a multi-functional
hub, the site will also house other activities such as food and
microbiology testing, which should foster diversity and synergy
between scientific applications of molecular testing.
The company will introduce new, proprietary synthesis technology
in the new facility, which will lead to increased quality and
reliability in its oligonucleotides production capabilities.
Quality standards implemented during construction are already among
the highest in the industry and supported by several
internationally recognized certifications such as ISO 9001:2008,
ISO 13485: 2003 and an FDA certification for GMP production.
Located in the central hub for a major courier service operator,
the new site offers unparalleled accessibility to the major cities
in the US, and will allow Eurofins Genomics to become the fastest
provider of genomics services in the marketplace. This should, in
turn, allow for faster, more seamless service delivery to
scientists nationwide. Furthermore, Louisville’s highly trained
workforce aligns well with the advanced production processes that
Eurofins Genomics and other biotech firms require.
Comment from Dr. Gilles Martin, Eurofins Scientific CEO: “We are
proud to open our newest genomics competence center in Louisville,
KY. Our ambition is to make it the most modern and innovative
facility of its kind in the world. This state-of-the-art laboratory
reflects the Group’s commitment to quality, innovation, and to
contributing to the advancement of scientific research and health
sciences around the globe.”
Comment from Matt Bevin, Governor of Kentucky: “We are pleased
to welcome Eurofins Scientific to Kentucky and excited about the
opportunity to create jobs in the promising career field of
genomics right here in Louisville. We are glad they will be taking
advantage of the many logistical capabilities that cannot easily be
replicated by other states. It is a testament to the quality of
Louisville’s workforce and further indication that Kentucky is open
for business.”
Comment from Greg Fisher, Mayor of Louisville: “Eurofins is a
great example of the type of global leader our city wants to
attract. A modern, innovative company that delivers, bringing
together two of our five main economic development clusters –
logistics, and lifelong wellness and aging care. Our city’s central
location, with world-class logistics, will help Eurofins get their
products in, tested and returned more efficiently than anywhere
else. This is a big win for Louisville as we continue to attract
and support leaders in these industries.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:
About Eurofins GenomicsEurofins Genomics is an
international leader for genomic products and services, including
DNA and RNA synthesis, DNA and next generation sequencing,
synthetic gene synthesis, and applied genomics. The company's
strengths are its commitment to the latest technology and lab
processes, strong customer orientation, fast service, and high
quality standards.
As a member of the Eurofins group, the genomics division
contains major offices and production facilities in the United
States, Europe, and Asia. Eurofins Genomics’ customers encompass a
wide variety of industries including life science, pharma,
diagnostics, food, agriculture, biotechnological and research
markets around the world. Visit www.eurofinsgenomics.com for more
information.
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With over 22,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160301006152/en/
Eurofins MWG Operon LLCNorth America: (+1) 1-800-688-2248Europe:
(+49) 8092 8289-77Asia: (+81)
03-5492-7001oligo-us@eurofins.comwww.eurofinsgenomics.comorInvestor
RelationsEurofins Scientific GroupPhone: + 32 2 766 1620E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024